Medisys looks to US with safety needle deal with Smiths
This article was originally published in Clinica
Shares in UK safety needle company Medisys rose 8% to £0.72 ($1) on news that Smiths Medical is to become its exclusive co-marketing partner for its Future range of products in North America, Japan and the UK. Medisys has received an initial $1 million cash payment and the deal allows for a further $3.95 million in relation to commercial launches.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.